#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction

Prague, March 8, 2022 – Hundreds of thousands of patients in the Czech Republic can soon look forward to a treatment that may positively influence the progression of their disease. The European Medicines Agency (EMA) approved the registration of Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure with preserved left ventricular ejection fraction at the beginning of March. It thus becomes the first drug that doctors can prescribe to all patients, regardless of ejection fraction status. EMA had previously approved empagliflozin for the treatment of patients with chronic heart failure with reduced ejection fraction and for the treatment of adults with inadequately controlled type 2 diabetes. The drug was developed by Boehringer Ingelheim.
Source: Heart Failure 8. 3. 2022

News Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis

A study published last year monitored the impact of diosmin on laboratory and clinical parameters related to the pathophysiology of chronic venous disease in patients.
Source: Venous Insufficiency 23. 4. 2020

News Efficacy and Tolerance of Dorzolamide/Timolol Combination With and Without Preservatives in Patients With Elevated Intraocular Pressure

The fixed combination of the carbonic anhydrase inhibitor dorzolamide and the locally acting beta-blocker timolol is indicated for the treatment of elevated intraocular pressure in patients with open-angle glaucoma. The comparison of the efficacy and tolerance of this combination with preservatives, associated among other things with eye irritation, and without them was the subject of the American study presented below.
Source: Treatment of Glaucoma 21. 8. 2020

News Should We Test for Alpha-1-Antitrypsin in All COPD Patients?

Approximately 1–2% of patients with chronic obstructive pulmonary disease (COPD) have an alpha-1-antitrypsin (AAT) deficiency. This is an underdiagnosed genetic disorder that leads to rapid progression of COPD, although it is initially amenable to therapeutic intervention. Therefore, it is necessary to improve early detection of affected individuals. General practitioners can play a crucial role in this process.
Source: Deficiency of Alpha-1-Antitrypsin 10. 2. 2020

Journal articles Rare diseases in the year 2019 – the Czech and international context

Author of the article: Milan Macek jr. Source: Časopis lékařů českých | 1/2019 4. 4. 2019

Journal articles Bleeding disorders in pregnancy

Author of the article: J. Procházková, M. Procházka, M. Lubušký Source: Česká gynekologie | 1/2013 1. 3. 2013

Journal articles Effect of resilience in women on the outcome of her first IVF/ICSI

Author of the article: Gabriela Ďurašková, Radek Hampl, J. Štěpán, M. Kupka Source: Česká gynekologie | 2/2014 21. 4. 2014

News Impact of Candesartan on Achieving Remission in Patients with Active IgA Nephropathy

IgA nephropathy is the most common glomerulonephritis worldwide and in the Czech Republic. The effect of candesartan (an angiotensin receptor blocker) on the remission of active IgA nephropathy in patients treated with steroid pulses and tonsillectomy was investigated by the randomized study presented below.
Source: Sartans in the Treatment of Hypertension 18. 4. 2020

News Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria

Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and their incidence continues to rise. The study presented below investigated the efficacy of therapy with the combination of ceftazidime/avibactam (a third-generation cephalosporin and a beta-lactamase inhibitor) in treating these infections compared to the 'best available antibiotic therapy' (BAT).
Source: Anti-Infectives 22. 8. 2023

Journal articles Hodgkin´s Lymhoma – the Treatment Aproaches Development and Current Trends

Author of the article: J. Kořen, M. Trněný Source: Klinická onkologie | Supplementum 3/2015 19. 10. 2015

News fSCIG in Elderly Patients with PID or SID in Real Clinical Practice

The work of a team of German and Dutch authors presents data on the real clinical use of 10% subcutaneous immunoglobulin facilitated by hyaluronidase (fSCIG) in elderly patients with primary (PID) or secondary (SID) immunodeficiency.
Source: Primary and Secondary Immunodeficiencies 12. 1. 2023

News Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?

Turkish authors in their study focused on the use of metamizole in addressing vasospasm in microsurgery. Using an animal model, they sought to answer the question of how this drug compares to lidocaine and papaverine.
Source: Analgesia 27. 5. 2020

News The Presence of COPD Worsens the Course of COVID-19 – Results of Epidemiological Studies

Among the at-risk populations during the current COVID-19 pandemic are older individuals and those suffering from chronic comorbidities. The presence of chronic obstructive pulmonary disease (COPD), according to available data, represents a negative prognostic factor increasing the risk of severe course and mortality.
Source: Treatment of Asthma and COPD 8. 4. 2020

News Adequate Compensation of a Hypertensive Patient According to Current ESC Guidelines – Case Study

A 65-year-old man, hypertensive, visits the general practitioner for a check-up. He reports recent shortness of breath during mild exertion (walking up stairs). Two months ago, he had acute sinusitis, for which he was prescribed antibiotics (penicillin V) by a specialist. He experiences hip pain and suffers from a runny nose in the spring (allergy?). He has been treated for hypertension for approximately 8 years.
Source: Sartans in the Treatment of Hypertension 29. 9. 2020

News With Dr. Miroslav Nečas, Ph.D., on the conclusions of the recent consensus of the expert panel on the practice of biological treatment of psoriasis

This February, an expert consensus on the use of bimekizumab in the treatment of psoriasis and psoriatic arthritis (PsA) was published based on a literature review of 102 articles, from which 19 relevant publications were selected. A panel of 9 dermatologists then voted to accept 14 consensus statements and recommendations, 12 of which received an 'A' grade, one a 'B' grade, and one a 'C' grade. We discuss key conclusions and recommendations with Dr. Miroslav Nečas, Ph.D., from the 1st Department of Dermatovenereology at MU and St. Anne's Faculty Hospital in Brno.
Source: Rheumatic Diseases 19. 6. 2024

News Current Insights into the Etiology of Community Pneumonia: Pneumococci Still Leading?

The etiology of community-acquired pneumonias has undergone certain changes since the beginning of the antibiotic era. According to current guidelines, it is still recommended to initiate empirical antibiotic therapy upon diagnosing community-acquired pneumonia. However, there are certain concerns associated with the recommendation of empirical antibiotic therapy, especially regarding the increasing occurrence of bacterial antibiotic resistance. The aim of the study presented below was to specify the most frequently isolated pathogens of community-acquired pneumonia between 1945 and 2020.
Source: Anti-Infectives 25. 3. 2022

Journal articles Gynecologic robotic surgery and our initial experience

Author of the article: R. Pilka, P. Dzvinčuk Source: Česká gynekologie | 6/2010 20. 12. 2010

News Trastuzumab Deruxtecan in Patients with HER2+ Metastatic Breast Cancer

Last year, results of studies published in the Lancet journal demonstrated a significant clinical benefit of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer (mBC) pre-treated with anti-HER2 therapy, in the 2nd or later lines of treatment compared to trastuzumab emtansine (DESTINY-Breast03 study, second interim overall survival analysis) and after failure of trastuzumab emtansine compared to physician's choice of therapy (DESTINY-Breast02 study).
Source: Ovarian and Breast Cancer 12. 3. 2024

News Brentuximab Vedotin and Relapsing/Refractory NHL with High Expression of CD30

A recently published study by authors from South Korea focused on examining the efficacy of brentuximab vedotin in patients with non-Hodgkin lymphomas (NHL) that highly express CD30 (i.e., > 30% CD30-positive tumor cells based on immunohistochemistry), where the disease had relapsed or was refractory to previous treatments.
Source: Hematologic Malignancies 7. 10. 2020

News Management of Musculoskeletal Issues in Hemophiliacs at a Glance

Musculoskeletal issues are among the most common complications of hemophilia. Prevention and early treatment are crucial, and this message is also addressed to specialists by the World Federation of Hemophilia (WFH) guidelines from 2020.
Source: Hemophilia with Movement 17. 5. 2022

News Prediabetes through the lens of current data and findings − and why hurry with intervention

Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and mortality worldwide. The most serious impact on the health of the organism is mainly due to the macrovascular complications of this disease. However, their occurrence was often recorded before the diagnosis of DM2 was confirmed. Prediabetes itself thus represents a condition associated with the risk of developing cardiovascular (CV) complications with all their prognostic implications for patients.
Source: Diabetes 27. 7. 2022

News Diagnosis, Treatment, and Outcomes Achieved in Patients with Non-Small-Cell Lung Cancer in Central Europe

In June 2020, the journal Radiology and Oncology published the results of an analysis of data from patients with stage III non-small-cell lung cancer (NSCLC) from a Central European registry. A large team led by Czech experts focused on the diagnostic and therapeutic procedures used and the treatment results achieved in real-world practice.
Source: Lung Cancer 6. 1. 2021

News Currently on the Issue of Interchangeability of Preparations with Levothyroxine in Practice

Levothyroxine (LT4) in oral form is the standard therapy for patients with hypothyroidism. Given the legislative possibility of generic substitution and the number of original and generic preparations containing LT4, its substitution is possible, though not recommended. What are the practical conclusions?
Source: Thyroid Disorders 17. 7. 2023

Journal articles Role of the transforming growth factor (TGF)-β signal pathway in haematopoiesis and studies of new inhibitors of this pathway in the treatment of lower-risk myelodysplastic syndrome

Author of the article: O. Fuchs, R. Bokorová Source: Transfuze a hematologie dnes | 4/2019 8. 11. 2019

News Bite-Sized Pieces from EHA 2021: Two New Findings on T-Cell Lymphoma

Can a molecule that is crucial for the sensitivity of adult T-cell lymphoma or leukemia (ATLL) to NK cell cytotoxicity be identified? And what conclusions were drawn from the testing of an antibody specific for TRBC1 in the investigation of T-lymphoproliferative disorders? These topics were also covered at the EHA 2021 congress, in the electronic poster presentation section.
Source: Hematologic Malignancies 15. 12. 2021

1 26 27 28 29 30 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#